Agilent technologies inc(A.US AI Earnings Summary)
A AI Earnings Summary (In-Depth)
2026 Q3 (Fiscal Year)
Core Highlights
All seven comparable metrics exceeded guidance, with the China market unexpectedly growing 9% YoY, becoming the biggest surprise.
- Stock Price Reaction: Following the earnings release, on August 27 (the first trading day after the report), the stock opened at $159.35, reached a high of $163.75 and a low of $155.46, and closed at $157.69, up 1.68% from the August 26 close of $155.08. The after-hours print of $160.00 (+3.17%) was not the official close. This was primarily driven by Q3 revenue and Non-GAAP Earnings Per Share (EPS) both exceeding the upper bound of management's expectations, as well as 9% YoY growth in China significantly outperforming the previous "flat" expectation, alleviating concerns about a slow recovery in the Chinese end-market.
- Market Expectations: Revenue of $1.88B was about 2.2% above the TradingView pre-earnings market expectation of $1.84B; Non-GAAP EPS (ex-tariff refund) of $1.56 was about 4.7% above the TradingView pre-earnings market expectation of $1.49 (including the tariff-refund benefit, Non-GAAP EPS was $1.62, also above the expectation).
- Performance vs. Own Guidance: Actual performance for this quarter met and exceeded all internal guidance. Actual revenue of $1.88B exceeded the upper guidance bound of $1.85B (approx. 2.2% higher); core revenue growth of 7.3% exceeded the upper guidance bound of 5.9% (approx. 2.1 percentage points higher); Non-GAAP EPS was $1.62 (including tariff refunds) or $1.56 (excluding tariff refunds), both higher than the upper guidance bound of $1.50 (approx. 8.7% higher).
- In a Nutshell: Leveraging the pricing and procurement benefits of the Ignite Operating System, Agilent delivered revenue and profits above the upper end of its guidance and announced a comprehensive upward revision of its FY2026 full-year financial outlook, with the stock closing at $157.69 on August 27, up 1.68%.
Quarterly Highlights
The seven major indicators this quarter all exceeded internal expectations, with the shift from a "flat" expectation in the China market to an actual 9% growth being the biggest surprise, contributing a significant portion of this quarter's beat.
Core revenue growth significantly exceeded the upper end of internal expectations: Core (constant currency organic growth) revenue growth reached 7.3% this quarter, approximately 2.1 percentage points higher than the upper bound of the guidance range provided last quarter; reported revenue was $1.88B, up 8.1% YoY. CEO Padraig McDonnell stated this resulted from commercial execution and the Ignite Operating System, rather than purely benefiting from end-market improvement.
China market grew 9% vs. flat expectations, driving the overall beat: China grew 9% YoY this quarter, far exceeding the "flat" expectation given last quarter, led by Pharma (double-digit growth) and Food (mid-double-digit growth). The CEO noted that growth mainly came from competitive wins with CXO customers, strong demand for PFAS testing, and AI infrastructure construction driving ~17%~19% growth in advanced materials business in China, with almost no impact from government stimulus policies.
Pharma end-market grew 12% YoY, far exceeding high-single-digit expectations; GLP-1 momentum grew over 70% YoY: Within the Pharma business, Biopharma grew double digits, and Small Molecule grew mid-single digits; the Advanced Therapeutics Division (ATD, including NASD and BioVectra specialty CDMO services) grew nearly 30%. GLP-1 related business grew over 70% YoY, spanning both CDMO and analytical laboratory business lines.
Non-GAAP EPS (excluding tariff refunds) grew 14% YoY, $0.06 above the upper bound of internal expectations: After excluding the $0.06 net benefit from tariff refunds, EPS was $1.56, which is $0.06 higher than the upper bound of the guidance range provided last quarter ($1.50); including the refund, EPS was $1.62. Non-GAAP operating margin (excluding tariff refunds) reached 27.2%, up 210 basis points YoY, 80 basis points higher than implied expectations.
Ignite Operating System drove strategic pricing contribution of ~200 basis points for three consecutive quarters, exceeding initial full-year targets: The CEO noted that FY2026 Q1, Q2, and Q3 each contributed about 200 basis points of pricing growth, exceeding the original full-year target of "over 100 basis points." Manufacturing customer request-to-delivery date performance reached a record high of 95%, and online new orders grew approx. 12%~13% QoQ.
New product launches performed better than expected; 9500 ICP-MS order funnel exceeded $60M: The 9500 Triple Quad ICP-MS began shipping in late July, already surpassing mass production targets with an order funnel over $60M; orders for the new flagship Gas Chromatographs (GC) 8890B and 8860B exceeded expectations by over 2x in the first two months; Altura biopharma column adoption by new accounts grew 28% QoQ.
Free cash flow reached $439M, with a 96% Non-GAAP net income conversion rate: Operating cash flow for the quarter was $519M, capital expenditures were $80M, and Free Cash Flow (FCF) was $439M. The 96% cash conversion rate of Non-GAAP net income reflects improved operational efficiency and accounts receivable collection, including the cash benefit from tariff refunds.
Pharma reshoring orders landed earlier than expected, with orders from five of the global top ten pharma companies in Q3: The CEO stated that pharma reshoring orders materialized ahead of schedule in Q3, coming from five of the global top ten pharma companies, and 75% of US Most Favored Nation (MFN) agreement signatories have been integrated into Agilent's strategic account program, helping capture global reshoring dynamics.